Sentiment-Signal
15,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
36.8
1 neu, 0 erhöht, -111149239K $ netto
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (05.02.2026)
HOCH Abgang Schlüsselpersonen (05.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 05.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 19.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 23.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 04.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 23.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 12.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 22.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 30.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 10.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 31.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 22.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e 2027 BSX27 New York Stock Exchange Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 27.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 31.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Unternehmen & Branche
| Name | BOSTON SCIENTIFIC CORP |
|---|---|
| Ticker | BSX |
| CIK | 0000885725 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | 101137107 |
|---|---|
| ISIN | US1011371077 |
| Typ | Common Stock |
| Marktkapitalisierung | 91,61 Mrd. USD |
| Beta | 0,78 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 20,074,000,000 | 1.94 | 43,673,000,000 | 24,233,000,000 | |
| 2025-09-30 | 10-Q | 5,065,000,000 | 0.51 | 42,707,000,000 | 23,394,000,000 | |
| 2025-06-30 | 10-Q | 5,061,000,000 | 0.53 | 41,559,000,000 | 22,418,000,000 | |
| 2025-03-31 | 10-Q | 4,663,000,000 | 0.45 | 40,140,000,000 | 22,212,000,000 | |
| 2024-12-31 | 10-K | 16,747,000,000 | 1.25 | 39,395,000,000 | 21,770,000,000 | |
| 2024-09-30 | 10-Q | 4,209,000,000 | 0.32 | 38,078,000,000 | 20,708,000,000 | |
| 2024-06-30 | 10-Q | 4,120,000,000 | 0.22 | 37,108,000,000 | 20,371,000,000 | |
| 2024-03-31 | 10-Q | 3,856,000,000 | 0.33 | 36,669,000,000 | 19,926,000,000 | |
| 2023-12-31 | 10-K | 14,240,000,000 | 1.07 | 35,136,000,000 | 19,282,000,000 | |
| 2023-09-30 | 10-Q | 3,527,000,000 | 0.34 | 34,043,000,000 | 18,886,000,000 | |
| 2023-06-30 | 10-Q | 3,599,000,000 | 0.18 | 33,601,000,000 | 18,226,000,000 | |
| 2023-03-31 | 10-Q | 3,389,000,000 | 0.21 | 32,892,000,000 | 17,850,000,000 | |
| 2022-12-31 | 10-K | 12,682,000,000 | 0.45 | 32,469,000,000 | 17,573,000,000 | |
| 2022-09-30 | 10-Q | 3,170,000,000 | 0.12 | 31,947,000,000 | 17,640,000,000 | |
| 2022-06-30 | 10-Q | 3,244,000,000 | 0.17 | 32,189,000,000 | 17,251,000,000 | |
| 2022-03-31 | 10-Q | 3,026,000,000 | 0.07 | 32,337,000,000 | 16,735,000,000 | |
| 2021-12-31 | 10-K | 11,888,000,000 | 0.69 | 32,229,000,000 | 16,622,000,000 | |
| 2021-09-30 | 10-Q | 2,932,000,000 | 0.28 | 31,877,000,000 | ||
| 2021-06-30 | 10-Q | 3,077,000,000 | 0.12 | 31,168,000,000 | ||
| 2021-03-31 | 10-Q | 2,752,000,000 | 0.23 | 30,900,000,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 139,685,997 | 0 | 139,685,997 | 13,319,059,814 | Neu | +100,0% | |
| BlackRock, Inc. | 135,987,245 | 0 | 135,987,245 | 12,966,383,785 | Neu | +100,0% | |
| FMR LLC | 97,386,941 | 0 | 97,386,941 | 9,285,844,832 | Neu | +100,0% | |
| STATE STREET CORP | 65,846,059 | 0 | 65,846,059 | 6,278,421,726 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 32,383,765 | 0 | 32,383,765 | 3,073,439,808 | Neu | +100,0% | |
| PRIMECAP MANAGEMENT CO/CA/ | 31,096,184 | 0 | 31,096,184 | 2,965,021,147 | Neu | +100,0% | |
| Capital World Investors | 27,151,575 | 0 | 27,151,575 | 2,588,953,114 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 25,842,686 | 0 | 25,842,686 | 2,464,100,230 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 25,115,185 | 0 | 25,115,185 | 2,394,732,919 | Neu | +100,0% | |
| NORGES BANK | 23,066,546 | 0 | 23,066,546 | 2,199,395,161 | Neu | +100,0% | |
| MORGAN STANLEY | 22,960,556 | 0 | 22,960,556 | 2,189,289,385 | Neu | +100,0% | |
| Blackstone Inc. | 22,201 | 0 | 22,201 | 2,116,865,000 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 16,792,417 | 0 | 16,792,417 | 1,601,156,850 | Neu | +100,0% | |
| UBS Group AG | 15,598,246 | 0 | 15,598,246 | 1,487,292,755 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 13,935,423 | 0 | 13,935,423 | 1,328,742,584 | Neu | +100,0% | |
| Invesco Ltd. | 13,318,177 | 0 | 13,318,177 | 1,269,888,192 | Neu | +100,0% | |
| JANUS HENDERSON GROUP PLC | 12,589,385 | 0 | 12,589,385 | 1,200,403,908 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 12,586,690 | 0 | 12,586,690 | 1,152,465,892 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 11,249,204 | 0 | 11,249,204 | 1,072,611,602 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 11,035,628 | 0 | 11,035,628 | 1,052,247,130 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 10,936,957 | 0 | 10,936,957 | 1,042,838,851 | Neu | +100,0% | |
| Legal & General Group Plc | 10,876,617 | 0 | 10,876,617 | 1,037,085,420 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 9,709,089 | 0 | 9,709,089 | 925,761,636 | Neu | +100,0% | |
| Fisher Asset Management, LLC | 9,138,216 | 0 | 9,138,216 | 871,328,966 | Neu | +100,0% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 9,085,528 | 0 | 9,085,528 | 866,305,096 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 8,946,503 | 0 | 8,946,503 | 853,049,061 | Neu | +100,0% | |
| PARNASSUS INVESTMENTS, LLC | 7,899,240 | 0 | 7,899,240 | 753,192,534 | Neu | +100,0% | |
| EDGEWOOD MANAGEMENT LLC | 7,803,265 | 0 | 7,803,265 | 744,041,318 | Neu | +100,0% | |
| FARALLON CAPITAL MANAGEMENT LLC | 7,439,564 | 0 | 7,439,564 | 709,362,427 | Neu | +100,0% | |
| Capital Research Global Investors | 7,084,055 | 0 | 7,084,055 | 675,466,628 | Neu | +100,0% | |
| CANADA PENSION PLAN INVESTMENT BOARD | 6,861,760 | 0 | 6,861,760 | 654,268,816 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 6,748,180 | 0 | 6,748,180 | 643,438,963 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 6,431,084 | 0 | 6,431,084 | 613,189,996 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 6,051,572 | 0 | 6,051,572 | 577,017,000 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 6,036,218 | 0 | 6,036,218 | 575,553,386 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 5,735,230 | 0 | 5,735,230 | 546,892,546 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 5,676,082 | 0 | 5,676,082 | 541,214,414 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 5,554,305 | 0 | 5,554,305 | 529,602,982 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 5,532,836 | 0 | 5,532,836 | 527,555,913 | Neu | +100,0% | |
| BARCLAYS PLC | 5,520,392 | 0 | 5,520,392 | 526,369,378 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 5,468,295 | 0 | 5,468,295 | 521,401,965 | Neu | +100,0% | |
| Egerton Capital (UK) LLP | 5,385,084 | 0 | 5,385,084 | 513,467,759 | Neu | +100,0% | |
| FIL Ltd | 4,758,079 | 0 | 4,758,079 | 453,682,833 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 4,654,828 | 0 | 4,654,828 | 443,837,807 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 4,602,194 | 0 | 4,602,194 | 438,819,197 | Neu | +100,0% | |
| Man Group plc | 4,392,725 | 0 | 4,392,725 | 418,846,329 | Neu | +100,0% | |
| Assenagon Asset Management S.A. | 4,306,176 | 0 | 4,306,176 | 410,593,882 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 4,299,773 | 0 | 4,299,773 | 410,012,869 | Neu | +100,0% | |
| Swiss National Bank | 4,060,500 | 0 | 4,060,500 | 387,168,675 | Neu | +100,0% | |
| Neuberger Berman Group LLC | 4,010,261 | 0 | 4,010,261 | 382,378,347 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-02 | Mahoney Michael F | Director, Officer, Chairman, President & CEO | Open Market Sale | -159,701 | 93.49 | -14,930,526.34 | -445,2% | |
| 2026-02-02 | Mahoney Michael F | Director, Officer, Chairman, President & CEO | Open Market Sale | -1,200 | 94.06 | -112,868.04 | -3,4% | |
| 2025-12-01 | Butcher Arthur C | Officer, EVP& Grp Pres, MedSurg & APAC | Open Market Sale | -17,313 | 101.55 | -1,758,188.82 | -52,4% | |
| 2025-11-06 | Zane Ellen M | Director | Open Market Sale | -12,891 | 98.28 | -1,266,977.75 | -37,8% | |
| 2025-11-03 | Fitzgerald Joseph Michael | Officer, EVP & Group Pres, Cardiology | Open Market Sale | -16,928 | 99.76 | -1,688,749.13 | -50,4% | |
| 2025-11-03 | Fitzgerald Joseph Michael | Officer, EVP & Group Pres, Cardiology | Open Market Sale | -29,472 | 99.14 | -2,921,895.34 | -87,1% | |
| 2025-11-03 | Fitzgerald Joseph Michael | Officer, EVP & Group Pres, Cardiology | Open Market Sale | -3,600 | 100.75 | -362,693.16 | -10,8% | |
| 2025-10-28 | Zane Ellen M | Director | Open Market Sale | -2,901 | 102.24 | -296,598.82 | -8,8% | |
| 2025-10-27 | Zane Ellen M | Director | Open Market Sale | -9,990 | 101.13 | -1,010,300.69 | -30,1% | |
| 2025-10-01 | Fitzgerald Joseph Michael | Officer, EVP & Group Pres, Cardiology | Open Market Sale | -41,755 | 98.38 | -4,107,844.37 | -122,5% | |
| 2025-10-01 | Fitzgerald Joseph Michael | Officer, EVP & Group Pres, Cardiology | Open Market Sale | -8,245 | 98.91 | -815,482.44 | -24,3% | |
| 2025-09-02 | Fitzgerald Joseph Michael | Officer, EVP & Group Pres, Cardiology | Open Market Sale | -21,830 | 104.89 | -2,289,661.38 | -68,3% | |
| 2025-09-02 | Fitzgerald Joseph Michael | Officer, EVP & Group Pres, Cardiology | Open Market Sale | -28,170 | 105.85 | -2,981,755.06 | -88,9% | |
| 2025-08-01 | Butcher Arthur C | Officer, EVP& Grp Pres, MedSurg & APAC | Open Market Sale | -17,313 | 104.63 | -1,811,519.79 | -54,0% | |
| 2025-08-01 | Fitzgerald Joseph Michael | Officer, EVP & Group Pres, Cardiology | Open Market Sale | -50,000 | 104.63 | -5,231,670.00 | -156,0% | |
| 2025-07-29 | FUJIMORI YOSHIAKI | Director | Open Market Sale | -2,901 | 106.99 | -310,377.99 | -9,3% | |
| 2025-07-25 | LUDWIG EDWARD J | Director | Open Market Sale | -4,000 | 106.03 | -424,120.40 | -12,6% | |
| 2025-07-01 | Fitzgerald Joseph Michael | Officer, EVP & Group Pres, Cardiology | Open Market Sale | -50,000 | 106.97 | -5,348,315.00 | -159,5% | |
| 2025-06-04 | Fitzgerald Joseph Michael | Officer, EVP & Group Pres, Cardiology | Open Market Sale | -56,372 | 102.88 | -5,799,630.28 | -172,9% | |
| 2025-06-02 | Mahoney Michael F | Director, Officer, Chairman, President & CEO | Open Market Sale | -89,921 | 103.39 | -9,296,950.17 | -277,2% | |
| 2025-06-02 | Mahoney Michael F | Director, Officer, Chairman, President & CEO | Open Market Sale | -74,522 | 104.05 | -7,754,185.50 | -231,2% | |
| 2025-05-29 | LUDWIG EDWARD J | Director | Open Market Sale | -4,000 | 104.59 | -418,367.60 | -12,5% | |
| 2025-05-21 | Brown Vance R | Officer, SVP, GC and Corp. Secretary | Open Market Sale | -4,826 | 106.42 | -513,582.92 | -15,3% | |
| 2025-05-05 | Sorenson John Bradley | Officer, EVP, Global Operations | Open Market Sale | -4,572 | 104.54 | -477,956.88 | -14,3% | |
| 2025-05-01 | Mahoney Michael F | Director, Officer, Chairman, President & CEO | Open Market Sale | -73,161 | 102.92 | -7,529,708.17 | -224,5% | |
| 2025-05-01 | Mahoney Michael F | Director, Officer, Chairman, President & CEO | Open Market Sale | -91,282 | 102.13 | -9,322,265.53 | -278,0% | |
| 2025-05-01 | Butcher Arthur C | Officer, EVP& Grp Pres, MedSurg & APAC | Open Market Sale | -17,314 | 102.06 | -1,766,982.00 | -52,7% |
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-03-31 | 684 | 62,93 | 43.044 |
| 2026-03-25 | 148 | 68,15 | 10.086 |
| 2026-03-24 | 50 | 69,54 | 3.477 |
| 2026-03-23 | 102.896 | 69,48 | 7.149.214 |
| 2026-03-11 | 413 | 69,96 | 28.893 |
| 2026-03-06 | 1.085 | 72,99 | 79.194 |
| 2026-02-19 | 458 | 76,28 | 34.936 |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| AVITY INVESTMENT MANAGEMENT INC. | 111,381 | 6,989,158 | 72.78 |
| OPPENHEIMER & CO INC | 35,335 | 2,217,271 | 23.09 |
| PW Nova Financial Services LLC | 6,314 | 396,204 | 4.13 |